The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, placebo-controlled, double blind, phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors.
 
Akihiko Takeuchi
Consulting or Advisory Role - Daiichi Sankyo
 
Makoto Endo
Honoraria - Asahi Kasei; Daiichi Sankyo; Eisai; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AYUMI
 
Akira Kawai
No Relationships to Disclose
 
Yoshihiro Nishida
Honoraria - Asahi Kasei; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; Eisai; Hisamitsu Pharmaceutical; Kaken Pharmaceutical; Kyowa Hakko Kirin Co., Ltd.; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Seikagaku
Research Funding - Novartis (Inst); Zimmer BioMet (Inst)
 
Ryu Terauchi
No Relationships to Disclose
 
Akihiko Matsumine
No Relationships to Disclose
 
Hisaki Aiba
No Relationships to Disclose
 
Tomoki Nakamura
No Relationships to Disclose
 
Susumu Tandai
No Relationships to Disclose
 
Toshifumi Ozaki
No Relationships to Disclose
 
Manabu Hoshi
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihonkayaku; Novartis; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku
 
Akihiro Nomura
No Relationships to Disclose
 
Toshinori Murayama
No Relationships to Disclose
 
Hiroyuki Tsuchiya
No Relationships to Disclose